Allergan plc Ordinary Shares (NYSE: AGN),
Alcon, Shire PLC (ADR) (NASDAQ: SHPG) and,
to a lesser extent, Bausch & Lomb are the active buyers of ophthalmology products/companies, according to a note from Bernstein
citing venture capitalist Emmett Cunningham.
Of note, Alcon is a subsidiary of Novartis AG (ADR) (NYSE: NVS) and Bausch & Lomb was acquired by Valeant Pharmaceuticals Intl
Inc (NYSE: VRX).
Cunningham is an ophthalmologist, a partner at Clarus Funds and a leading venture capitalist in the eye-care space.
Related Link: JPMorgan
Sees "Shaxalta" Upside Potential At 36%
"We wonder if Shire is not highly motivated to buy one of the two Glaucoma companies – Aerie or Inotek," analyst Aaron "Ronny"
Gal posed.
In addition to the top active buyers, Gal looked further into the sector.
The note said, Genentech is active in ophthalmology but are only looking for large improvement over standard of care
(first-in-class/best-in class)," while Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is somewhat active in the space as well.
Bernstein rates Allergan at Outperform, with a price target of $335. Shire is also rated Outperform, with a price target of
$222.
At the time of writing, shares of Allergan were down 1.26 percent to $246.81, and Regeneron Pharma dropped 0.65 percent to
$386.44. Meanwhile, ADRs of Shire also fell 1.45 percent to $185.88.
Latest Ratings for AGN
| Date |
Firm |
Action |
From |
To |
| Apr 2016 |
Piper Jaffray |
Downgrades |
Overweight |
Neutral |
| Apr 2016 |
Guggenheim Securities |
Initiates Coverage on |
|
Neutral |
| Apr 2016 |
Goldman Sachs |
Reinstates |
|
Buy |
View More Analyst Ratings for
AGN
View the Latest Analyst Ratings
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.